Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tumor Cells Profiled by Microscopic Imaging

By LabMedica International staff writers
Posted on 22 May 2012
A hyperspectral microscopic imaging (HMI) platform can precisely identify and quantify 10 molecular markers in individual cancer cells in a single pass.

Improved capture of circulating tumor cells and hyperspectral microscopic imaging facilitate identification and quantification of many molecular markers in cells at different times, recognition of coexpression of markers, and, thereby, allow noninvasive diagnosis and improved targeted therapy.

Scientists at the University of Texas Southwestern Medical Center (Dallas, TX, USA) analyzed normal and tumor cells using an HMI platform. They balanced the intensity of 10 fluorochromes bound to 10 different antibodies, each specific to a particular tumor marker, so that the intensity of each fluorochrome can be discerned from overlapping emissions.

By using two touch preparations from each primary breast cancer, the average molecular marker intensities of 25 tumor cells gave a representative molecular signature for the tumor despite some cellular heterogeneity. The HMI system is composed of an Olympus IX-70 inverted microscope (Olympus; Center Valley, PA, USA), SP-500i imaging spectrograph (Acton Research Corporation; Acton, MA, USA), Quantix KAF1600 charge-coupled device (CCD) camera (Photometrics, Tucson, AZ, USA), and X-Y motorized stage (Ludl Electronic Products Ltd.; Hawthorne, NY, USA).

The team quantified 10 molecular markers in 25 cells from five different cancer cell lines and two normal breast epithelial cell lines, providing 1,700 measurements of tumor marker intensity. The intensities determined by the HMI correlate well with the conventional analysis by experts in cellular pathology. Because additional multiplexes can be developed using the same fluorochromes but different antibodies, this analysis allows quantification of many molecular markers on a population of tumor cells. HMI can be automated completely, and eventually, it could allow the standardization of protein biomarkers and improve reproducibility among clinical pathology laboratories.

The authors concluded that conventional pathologic examination together with current fluorescence microscopy is insufficient to obtain the level of molecular profiling necessary to optimize new treatment regimens. However, HMI analysis of touch preparations of tumor tissue and circulating tumor cells represents a major step forward because a large number of molecular markers can be detected and their expression precisely quantified in individual tumor cells. The study was published in the May 2012 issue of Translational Research.

Related Links:

University of Texas Southwestern Medical Center
Olympus
Acton Research Corporation



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.